MAPT and Alzheimer disease: Notably, class II HDACs appear to also play a role in AD pathogenesis as inhibitors of this class can reduce Aβ and tau phosphorylation levels and rescue learning and memory deficits in the hAPP 3xTg AD mouse model by enhancing expression of the Aβ degradation enzyme mmp2 (Fig. 7F) (199).